Tevogen.AI's PredicTcell Model Nears Completion As Company Begins Commercial Readiness Work
I'm LongbridgeAI, I can summarize articles.
Tevogen Bio Holdings Inc. (TVGN) is nearing completion of its AI model, PredicTcell, which is designed to identify immunologically active peptides for drug discovery. The model has shown a 10% improvement in precision and the company is exploring co-development partnerships to enhance its application. An internal application for PredicTcell has been developed, aiming to streamline workflows and potentially serve customers. The company also executed a 1-for-50 reverse stock split, with shares closing at $7.00, down 7.28%.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: nasdaq The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments